Five promising early-stage life science ventures are beginning the next steps of their entrepreneurial adventure at one of the most successful locations for life science start-ups in Europe, the Babraham Research Campus, Cambridge.
Babraham Bioscience Technologies Ltd, which manages and develops the Babraham Research Campus on behalf of its shareholders - BBSRC and the Babraham Institute – is now known as Babraham Research Campus Ltd.
Transine Therapeutics, a biotechnology company developing a novel class of therapeutic RNAs based on its pioneering SINEUP® platform technology, today announced the appointment of Jan Thirkettle, PhD as its Chief Executive Officer.
Transine Therapeutics closes extended seed funding of £9.1m to advance its novel class of therapeutic RNAs
New company emerges from stealth with potential ground-breaking mRNA therapeutic platform to increase protein expression.
The Babraham Research Campus vision is to be one of the best places in the world for discovery bioscience research and innovation; a leading sustainable ecosystem to start, nurture, scale and grow bioscience business.
Accelerate@Babraham, the bio-entrepreneurial incubator initiative founded and developed by the Babraham Research Campus - supported by key industry and investor organisations - opens applications for its 2021/22 cohort today.
Alchemab to collaborate with AstraZeneca to use Alchemab’s drug discovery platform for prostate cancer study
Alchemab, a biotech company developing novel therapeutics for patients with hard-to-treat diseases by harnessing the power of naturally protective antibodies, has formed a collaboration with AstraZeneca to accelerate prostate cancer research.
Alchemab raises £60 million in Series A financing to advance novel platform for identifying disease-modifying antibody therapeutics
Alchemab Therapeutics, a biotech company developing novel products for patients with hard-to-treat diseases by harnessing the power of naturally protective antibodies, today announces the completion of a £60 million ($82 million) Series A financing round.
Babraham Bioscience Technologies Ltd (BBT), the organisation which oversees the development and day-to-day management of the Babraham Research Campus is delighted to confirm Jo Parfrey as the new BBT Board Chair.
Kidney Research UK confirmed as new strategic partner to the Babraham Research Campus Accelerate@Babraham initiative
The Babraham Research Campus is delighted to welcome the charity Kidney Research UK as the latest organisation to pledge strategic and financial support to its Accelerate@Babraham initiative. The additional funding boosts the ability of the Campus to continue to support and sustain innovation in early science concepts and nurture new life science companies across the Cambridge cluster.
Babraham Bioscience Technologies Ltd (BBT), the organisation which oversees the development and day-to-day management of the Babraham Research Campus, is pleased to welcome three new members to its board.
Paediatric HealthTech wins Accelerate@Babraham with AstraZeneca Start-up Pitching Competition to secure £10,000
The Babraham Research Campus’ third cohort of Accelerate@Babraham life science start-ups - ArkVax, Paediatric HealthTech, ConcR and Stroma Biosciences - went head-to-head yesterday (Weds); competing for £10,000 additional funding generously donated by CMS Ventures in the Accelerate@Babraham with AstraZeneca: Start-up Pitching Competition.
Closed Loop Medicine recruits first patient into clinical trial for patients with high blood pressure
Closed Loop Medicine (CLM), a clinical stage therapeutics company developing drug + digital combination products, announces that the first patient has been recruited into its pivotal clinical trial investigating CLM’s integrated precision care solution for patients with hypertension.
Cell Guidance Systems Ltd, a specialist in exosome research reagents and services, today announced the launch of a new product for the purification of exosomes from blood and other samples. The Exo-spin™ 96 exosome purification kit allows researchers to purify exosome samples in the standard 96 well plate format.
Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycles®) technology, today reported financial results for the third quarter ended September 30, 2020 and discussed recent corporate updates.
Babraham Research Campus seeks independent non-executive directors to help set future strategy and development of the campus
Babraham Bioscience Technologies (BBT), which is responsible for the management and commercial development of the Babraham Research Campus, today announced two new Board positions.
Accelerate@Babraham Start-up Programme underway with four new life science start-ups taking part in five month programme
The Babraham Research Campus’ third cohort of Accelerate@Babraham life science start-ups came together yesterday (Monday) for the first day of the 2020/21 programme.
Atelerix awarded Innovate UK funding to enable transport and storage of cellular therapies at room temperature
Atelerix Ltd, pioneers in the storage and transport of cells at room temperature, has received a significant award under the UK Innovation and Science Seed Fund (UKI2S) Accelerator Programme from Innovate UK, the UK’s innovation agency. The funding will support the development of room temperature solutions for shipping therapeutic cells, as part of the company’s “BloodReady” project.
Reflection Therapeutics secures Innovate UK co-funding for major research programme to fight motor neurone disease through cell therapy
Reflection Therapeutics, Cambridge-based developer of cell therapy against neuroinflammation, is pleased to announce the start of a major Innovate Smart Grant project co-funded by Innovate UK, the UK’s innovation agency.
Closed Loop Medicine has secured £250,000 from Innovate UK to support clinical evaluation of a drug + digital combination product for hypertension and COVID- 19 monitoring.
New report confirms Babraham Research Campus at the forefront in supporting the UK’s early-stage bioscience enterprises
Research led by an academic team from the University of Cambridge has demonstrated the benefits and outputs from the significant taxpayer investment into the Babraham Research Campus; evidencing the overall economic, social and scientific contribution the Campus makes to the UK economy.
Mission Therapeutics, a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), today announces its move to new purpose-built headquarters on the Babraham Research Campus, Cambridge.
Eisai joins AstraZeneca, LifeArc and Mundipharma in providing funding towards the continued development of the Babraham Research Campus bio-incubator programme, supporting early-stage science and new life science companies within the Cambridge cluster.
Applications for Accelerate@Babraham, designed to support early stage life science ventures, will close on June 17th 2020.